Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18412671 | 0.90 | KDM4E (0.32) | KDM4EREN | |
| SCHEMBL18412666 | 0.85 | KDM4E (0.35) | KDM4EUSP2SLCO1B1 | |
| SCHEMBL18412668 | 0.77 | REN (0.30) | REN | |
| SCHEMBL11729548 | 0.71 | PDE4A (0.52) | KDM4EUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL11729532 | 0.71 | PDE4A (0.52) | KDM4EUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL1964137 | 0.69 | LMNA (0.58) | KDM4EUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL19741239 | 0.69 | LMNA (0.58) | KDM4EUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL2297555 | 0.69 | LMNA (0.58) | KDM4EUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL92729 | 0.69 | LMNA (0.58) | KDM4EUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL1668363 | 0.69 | LMNA (0.58) | KDM4EUSP2SLCO1B1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9849129-B2 | Sodium channel blockers for skin disorders | PARION SCIENCES, INC. (US) | 2017-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | SCNN1B, SCNN1A, SCNN1G | KDM4E 3964/4885USP2 2929/4885SLCO1B1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.